The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: A meta-analysis

American Journal of Gastroenterology

Volumn 101, Issue 7, 2006, Pages 1467-1475

  Padol, Sara ^a   Yuan, Yuhong ^a   Thabane, Marroon ^a   Padol, Ireneusz T ^a   Hunt, Richard H ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

CLINICAL TRIAL; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG METABOLISM; ERADICATION THERAPY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HETEROZYGOUS EXTENSIVE METABOLIZER; HUMAN; META ANALYSIS; POOR METABOLIZER; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; BENZIMIDAZOLES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PROTON PUMPS;

EID: 33745524102     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00717.x     Document Type: Review

References (41)

1. Buckley M, O'Morain C. Prevalence of Helicobacter pylori in non-ulcer dyspepsia. Aliment Pharmacol Ther 1995;9(suppl 2):53-8.
2. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
3. Marshall BJ, Windsor HM. The relation of Helicobacter pylori to gastric adenocarcinoma and lymphoma: Pathophysiology, epidemiology, screening, clinical presentation, treatment, and prevention. Med Clin North Am 2005;89:313-44.
4. McNamara D, Buckley M, Gilvarry J, et al. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: A 5-year follow-up study. Helicobacter 2002;7:317-21.
5. Tytgat GN. No Helicobacter pylori, no Helicobacter pylori-associated peptic ulcer disease. Aliment Pharmacol Ther 1995;9(suppl 1):39-42.
6. Uemura N, Okamoto S. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer in Japan. Gastroenterol Clin North Am 2000;29:819-27.
7. Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: Relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997;39:5-12.
8. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-67.
9. Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998;43:S56-S60.
10. Scott DR, Weeks D, Hong C, et al. The role of internal urease in acid resistance of Helicobacter pylori. Gastroenterology 1998;114:58-70.
11. Kawakami Y, Akahane T, Yamaguchi M, et al. In vitro activities of rabeprazole, a novel proton pump inhibitor, and its thioether derivative alone and in combination with other antimicrobials against recent clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000;44:458-61.
12. Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004;5:181-202.
13. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997;7:59-64.
14. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy: Clinical implications. Am J Pharmacogenomics 2003;3:303-15.
15. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials 1996;17:1-12.
16. He XX, Zhao YH, Hao YT. Effect of CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with rabeprazole-based triple therapy in Chinese. Zhonghua Nei Ke Za Zhi 2004;43:13-5.
17. Tanabe H, Watari J, Shibata N, et al. Usefulness of new triple therapy containing PPI. Nippon Rinsho 2001;59:314-8.
18. Sheu BS, Kao AW, Cheng HC, et al. Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism. Aliment Pharmacol Ther 2005;21:283-8.
19. Isomoto H, Inoue K, Furusu H, et al. Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori. Helicobacter 2003;8:111-9.
20. Hokari K, Sugiyama T, Kato M, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. Aliment Pharmacol Ther 2001;15:1479-84.
21. Okudaira K, Furuta T, Shirai N, et al. Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. Aliment Pharmacol Ther 2005;21:491-7.
22. Kawabata H, Habu Y, Tomioka H, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin. Aliment Pharmacol Ther 2003;17:259-64.
23. Lee SB, Park SJ, Ryu JK, et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection in relation to CYP2C19 genotype. Korean J Gastroenterol 2003;42:468-75.
24. Sapone A, Vaira D, Trespidi S, et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. Am J Gastroenterol 2003;98:1010-5.
25. Miki I, Aoyama N, Sakai T, et al. Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan. Eur J Gastroenterol Hepatol 2003;15:27-33.
26. Take S, Mizuno M, Ishiki K, et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 2003;98:2403-8.
27. Inaba T, Mizuno M, Kawai K, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002;17:748-53.
28. Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69:158-68.
29. Dojo M, Azuma T, Saito T, et al. Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan. Dig Liver Dis 2001;33:671-5.
30. Miyoshi M, Mizuno M, Ishiki K, et al. A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism. J Gastroenterol Hepatol 2001;16:723-8.
31. Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001;11:341-8.
32. Tanigawara Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999;66:528-34.
33. Aoyama N, Tanigawara Y, Kita T, et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers. J Gastroenterol 1999;34(suppl 11):80-3.
34. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998;129:1027-30.
35. Chong E, Ensom MH. Pharmacogenetics of the proton pump inhibitors: A systematic review. Pharmacotherapy 2003;23:460-71.
36. Furuta T, Shirai N, Ohashi K, et al. Therapeutic impact of CYP2C19 pharmacogenetics on proton pump inhibitor-based eradication therapy for Helicobacter pylori. Methods Find Exp Clin Pharmacol 2003;25:131-43.
37. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004;95:2-8.
38. Lehmann DF, Medicis JJ, Franklin PD. Polymorphisms and the pocketbook: The cost-effectiveness of cytochrome P450 2C19 genotyping in the eradication of Helicobacter pylori infection associated with duodenal ulcer. J Clin Pharmacol 2003;43:1316-23.
39. Horn J. Review article: Relationship between the metabolism and efficacy of proton pump inhibitors - focus on rabeprazole. Aliment Pharmacol Ther 2004;20(suppl 6):11-9.
40. Roots I, Gerloff T, Meisel C, et al. Pharmacogenetics-based new therapeutic concepts. Drug Metab Rev 2004;36:617-38.
41. Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004;76:201-9.